Press Release - No. 4 / 2017
Zealand to present at two international healthcare investor conferences in June 2017
Copenhagen, June 2, 2017 - Zealand announces that its President and CEO, Britt Meelby Jensen, and Executive Vice
President and CFO, Mats Blom, will present the Company and host investor meetings at the following healthcare investor forums
taking place in New York and London in June 2017.
Jefferies 2017 Healthcare Conference, New York - June 6-7, 2017
Zealand Pharma A/S is presenting on: Tue, Jun 6 at 4:30-4:55 PM in 5 Ballroom (breakout at 5:00 PM-05:25 PM in Alvin Room).
Britt Meelby Jensen, President and CEO and Mats Blom, Executive Vice President and CFO, will represent the Company.
Citi 2016 Global Healthcare Conference, London - June 21, 2017
Zealand will host one-on-one investor meetings. Britt Meelby Jensen, President and CEO will represent the Company.
Please note that no new financial or other material information relating to Zealand and its business will be disclosed at these
meetings.
For further information, please contact:
Britt Meelby Jensen, President and CEO
Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com
Mats Blom, Executive Vice President, Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and
development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license
collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of internal product candidates focusing on specialty
gastrointestinal and metabolic diseases.
2
Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes,
is licensed to Sanofi. Lixisenatide is marketed as Adlyxin® in the U.S. and as Lyxumia® in the rest of the
world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus®) and is marketed as
Soliqua® 100/33 in the U.S. and has been approved as Suliqua® in Europe and launched in the Netherlands.
Zealand's clinical pipeline includes: dasiglucagon* (ZP4207, single-dose rescue treatment) for acute, severe hypoglycemia (Phase
2); glepaglutide* (ZP1848) for short bowel syndrome (Phase 2); dasiglucagon* (ZP4207, multiple-dose version) intended for use in a
dual-hormone artificial pancreas system to reduce the risk of hypoglycemia and better diabetes management (Phase 2) and other
earlier-stage clinical and preclinical peptide therapeutics.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please
visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.
* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN).
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/15bac858-889f-450d-943a-e132d731a3b0
